The Celgene-backed cancer drug specialist adds the IDG-Accel China Growth Fund to its investors.

The founder of Genentech says the sector is the biggest "loss-maker" for VCs meaning a potential funding drought.

The Fidelity-backed cancer drug developer has postponed its $191m IPO after setting the range, according to reports.

InTouch, which uses telecom and robotics technology to develop new healthcare techniques, formalises its development agreement with robotics specialist iRobot, which is investing $6m.

Targovax, developer of a vaccine based on research conducted at a Norsk Hydro-sponsored research institute, raises $2.2m, with a further $1m committed for its next round.

The University of Toronto-spin-out which works on molecular diagnostics has landed $10m in a series A round partially funded by Qiagen, a testing technology company.

The molecular diagnostics startup has landed $10m in a series A round partially funded by Qiagen, a molecular diagnostics and testing technology company.

The orthopaedic specialist has raised $89m in a series E round supported by investment group Axel Johnson and Asia-based government-backed investment funds.